Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 321

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 321
---
 or in the aggregate, a Company Material Adverse Effect and (c) none of the Company nor any of its Subsidiaries has taken any action that,
if taken after the date of this Agreement would require Parent’s consent pursuant to subsection (ii), (vi), (xii), (xiii), (xv), (xviii) or (xxi) of or, solely with respect to the foregoing
subsections, subsection (xxiii) of .

Section 4.10 No Undisclosed Material Liabilities. There are no liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due, of the Company or any of its Subsidiaries that would be required by GAAP
to be reflected on a consolidated balance sheet (or disclosed in the notes thereto), other than: (a) liabilities or obligations disclosed or otherwise reserved against in the Company Balance Sheet or in the consolidated financial statements of
the Company and its Subsidiaries (including the notes thereto) included in the Company SEC Documents filed prior to the date of this Agreement; (b) liabilities or obligations incurred in the ordinary course of business since the Company Balance
Sheet Date; (c) executory obligations arising under Contracts to which the Company or any of its Subsidiaries is a party (other than as a result of a breach thereof or default thereunder by the Company or any of its Subsidiaries); (d)
liabilities or obligations incurred in connection with the transactions contemplated by this Agreement (including the Mergers); and (e) liabilities or obligations that would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect.

Section 4.11 Litigation. Except as would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, from January 1, 2022, (a) there is and there has been no Proceeding pending against or threatened in writing against or, to the Knowledge of the Company, involving the Company
or any of its Subsidiaries and (b) neither the Company nor any of its Subsidiaries is or has been subject to any outstanding Order. As of the date hereof, there is no pending Proceeding or outstanding Order that seeks to prevent, materially
impair or materially delay consummation of the Mergers.

Section 4.12 Compliance with Applicable Law.

(a